{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:02:44Z","timestamp":1784354564950,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jdin.2023.12.010","type":"journal-article","created":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T23:32:40Z","timestamp":1705188760000},"page":"23-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The efficacy and safety of minocycline, metronidazole, ivermectin, and azelaic acid in moderate-to-severe papulopustular rosacea: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"20","author":[{"given":"Esraa A.","family":"Shaheen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara E.","family":"Aljefri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah A.","family":"Ghaddaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid M.","family":"Alshareef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer K.","family":"Alhindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narin F.","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar R.","family":"Alrashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3866-1421","authenticated-orcid":false,"given":"Abdulhadi","family":"Jfri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jdin.2023.12.010_bib1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/1346-8138.16254","article-title":"Metronidazole gel (0.75%) in Japanese patients with rosacea: a randomized, vehicle-controlled, phase 3 study","volume":"49","author":"Miyachi","year":"2022","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2023.12.010_bib2","first-page":"282","article-title":"Incidence and prevalence of rosacea: a systematic review and meta-analysis","volume":"179","author":"Gether","year":"2018","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jdin.2023.12.010_bib3","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1111\/jocd.14816","article-title":"Rosacea management: a comprehensive review","volume":"21","author":"Sharma","year":"2022","journal-title":"J Cosmet Dermatol"},{"issue":"12","key":"10.1016\/j.jdin.2023.12.010_bib4","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1097\/CM9.0000000000002151","article-title":"Summarization and comparison of dermoscopic features on different subtypes of rosacea","volume":"135","author":"Fei","year":"2022","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"10.1016\/j.jdin.2023.12.010_bib5","first-page":"149","article-title":"Advances in the treatment of rosacea-associated facial erythema","volume":"5","author":"Wang","year":"2022","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.jdin.2023.12.010_bib6","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jaad.2014.05.036","article-title":"The psychological impact of rosacea and the influence of current management options","volume":"71","author":"Moustafa","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"1-2","key":"10.1016\/j.jdin.2023.12.010_bib7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000446215","article-title":"Rosacea management","volume":"2","author":"Abokwidir","year":"2016","journal-title":"Skin Appendage Disord"},{"issue":"4","key":"10.1016\/j.jdin.2023.12.010_bib8","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/bjd.20485","article-title":"British Association of Dermatologists guidelines for the management of people with rosacea 2021","volume":"185","author":"Hampton","year":"2021","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jdin.2023.12.010_bib9","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3390\/antibiotics10070757","article-title":"A review of systemic minocycline side effects and topical minocycline as a safer alternative for treating acne and rosacea","volume":"10","author":"Martins","year":"2021","journal-title":"Antibiotics (Basel)"},{"issue":"3","key":"10.1016\/j.jdin.2023.12.010_bib10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s13555-018-0249-y","article-title":"Topical ivermectin in the treatment of papulopustular rosacea: a systematic review of evidence and clinical guideline recommendations","volume":"8","author":"Ebbelaar","year":"2018","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.jdin.2023.12.010_bib11","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1186\/s40064-016-2819-8","article-title":"The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis","volume":"5","author":"Siddiqui","year":"2016","journal-title":"Springerplus"},{"issue":"10","key":"10.1016\/j.jdin.2023.12.010_bib12","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jdin.2023.12.010_bib13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2147\/CCID.S139352","article-title":"An empirically generated responder definition for rosacea treatment","volume":"10","author":"Staedtler","year":"2017","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.jdin.2023.12.010_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.jdin.2023.12.010_bib15","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archderm.1987.01660290077020","article-title":"Topical metronidazole therapy for rosacea","volume":"123","author":"Bleicher","year":"1987","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jdin.2023.12.010_bib16","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/000155599750009906","article-title":"Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo-pustular rosacea","volume":"79","author":"Bjerke","year":"1999","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.jdin.2023.12.010_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1468-3083.2008.02940.x","article-title":"Comparative study of some treatment modalities of rosacea","volume":"23","author":"Mostafa","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jdin.2023.12.010_bib18","first-page":"306","article-title":"Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study","volume":"92","author":"Draelos","year":"2013","journal-title":"Cutis"},{"issue":"3","key":"10.1016\/j.jdin.2023.12.010_bib19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40257-017-0339-0","article-title":"A phase II, randomized, double-blind clinical study evaluating the safety, tolerability, and efficacy of a topical minocycline foam, FMX103, for the treatment of facial papulopustular rosacea","volume":"19","author":"Mrowietz","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2023.12.010_bib20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/bjd.18857","article-title":"A multicentre, randomized, double-masked, parallel group, vehicle-controlled phase IIb study to evaluate the safety and efficacy of 1% and 3% topical minocycline gel in patients with papulopustular rosacea","volume":"183","author":"Webster","year":"2020","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jdin.2023.12.010_bib21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/BF03259203","article-title":"A double-blind randomised study of metronidazole (Flagyl\u00ae) 1% cream in the treatment of acne rosacea","volume":"2","author":"Bitar","year":"1990","journal-title":"Drug Invest"},{"issue":"11","key":"10.1016\/j.jdin.2023.12.010_bib22","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1001\/archderm.139.11.1444","article-title":"A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial","volume":"139","author":"Elewski","year":"2003","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2023.12.010_bib23","first-page":"54","article-title":"A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea","volume":"96","author":"Draelos","year":"2015","journal-title":"Cutis"},{"issue":"sup1","key":"10.1016\/j.jdin.2023.12.010_bib24","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.3109\/09546639309082150","article-title":"Topical azelaic acid in the treatment of rosacea","volume":"4","author":"Carmichael","year":"1993","journal-title":"J Dermatol Treat"},{"issue":"3","key":"10.1016\/j.jdin.2023.12.010_bib25","first-page":"187","article-title":"Investigator-reported efficacy of azelaic acid foam 15% in patients with papulopustular rosacea: secondary efficacy outcomes from a randomized, controlled, double-blind, phase 3 trial","volume":"98","author":"Solomon","year":"2016","journal-title":"Cutis"},{"issue":"4","key":"10.1016\/j.jdin.2023.12.010_bib26","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.13408","article-title":"Superiority of ivermectin 1% cream over metronidazole 0\u00b775% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial","volume":"172","author":"Taieb","year":"2015","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2023.12.010_bib27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000065849","article-title":"Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study","volume":"205","author":"Ko\u00e7ak","year":"2002","journal-title":"Dermatology"},{"issue":"6 Pt 1","key":"10.1016\/j.jdin.2023.12.010_bib28","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0190-9622(99)70085-X","article-title":"A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea","volume":"40","author":"Maddin","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jdin.2023.12.010_bib29","first-page":"346","article-title":"Evaluation of topical metronidazole gel in acne rosacea","volume":"21","author":"Aronson","year":"1987","journal-title":"Drug Intell Clin Pharm"},{"issue":"6","key":"10.1016\/j.jdin.2023.12.010_bib30","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1067\/mjd.2003.308","article-title":"Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies","volume":"48","author":"Thiboutot","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2023.12.010_bib31","first-page":"316","article-title":"Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies","volume":"13","author":"Stein","year":"2014","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.jdin.2023.12.010_bib32","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jaad.2020.01.043","article-title":"Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: results of 2 phase 3, randomized, clinical trials","volume":"82","author":"Gold","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"22","key":"10.1016\/j.jdin.2023.12.010_bib33","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1001\/jama.2015.15287","article-title":"Interventions for rosacea","volume":"314","author":"van Zuuren","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jdin.2023.12.010_bib34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bjd.17590","article-title":"Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments","volume":"181","author":"van Zuuren","year":"2019","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jdin.2023.12.010_bib36","first-page":"639","article-title":"A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy","volume":"8","author":"Thiboutot","year":"2009","journal-title":"J Drugs Dermatol"},{"issue":"15","key":"10.1016\/j.jdin.2023.12.010_bib37","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1517\/14656566.9.15.2699","article-title":"Azelaic acid 15% gel in the treatment of rosacea","volume":"9","author":"Gollnick","year":"2008","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.jdin.2023.12.010_bib38","first-page":"37","article-title":"Azelaic acid topical formulations: differentiation of 15% gel and 15% foam","volume":"10","author":"Del Rosso","year":"2017","journal-title":"J Clin Aesthet Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2023.12.010_bib39","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1060028020939926","article-title":"Minocycline topical foam: a new drug for the treatment of acne","volume":"55","author":"Onge","year":"2021","journal-title":"Ann Pharmacother"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328724000075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328724000075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:58:15Z","timestamp":1747187895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328724000075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":38,"alternative-id":["S2666328724000075"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2023.12.010","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and safety of minocycline, metronidazole, ivermectin, and azelaic acid in moderate-to-severe papulopustular rosacea: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2023.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}